A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Combination With Metformin in Asian Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone.
Latest Information Update: 24 May 2024
At a glance
- Drugs Dapagliflozin (Primary) ; Metformin; Pioglitazone
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors AstraZeneca
- 23 May 2024 Results investigating (n=249 )the efficacy and safety of pioglitazone compared to placebo when added to metformin plus dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, for patients with type 2 diabetes mellitus , published in the Diabetes, Obesity and Metabolism
- 28 Sep 2012 New source identified and integrated (Clinical Trials Registry - India; CTRI2010-091-000430).
- 18 Jun 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.